Cell-based immunotherapy of prion diseases by adoptive transfer of antigen-loaded dendritic cells or antigen-primed CD4+ T lymphocytes

References

• Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci USA 2001; 98:9295 - 9299
   PubMed Web of Science ®Google Scholar
• Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001; 412:739 - 743
   PubMed Web of Science ®Google Scholar
• Heppner FL, Musahl C, Arrighi I, Klein MA, Rulicke T, Oesch B, et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 2001; 294:178 - 182
   PubMed Web of Science ®Google Scholar
• White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003; 422:80 - 83
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM, Sy MS, Li R, Scholtzova H, Kascsak RJ, Kascsak R, et al. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci Lett 2003; 336:185 - 187
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400:173 - 177
   PubMed Web of Science ®Google Scholar
• Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 2005; 46:857 - 868
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Sigurdson CJ. Antiprion immunotherapy: to suppress or to stimulate?. Nat Rev Immunol 2004; 4:725 - 736
   PubMed Web of Science ®Google Scholar
• Muller-Schiffmann A, Korth C. Vaccine approaches to prevent and treat prion infection: progress and challenges. BioDrugs 2008; 22:45 - 52
   PubMed Web of Science ®Google Scholar
• Sadowski MJ, Pankiewicz J, Prelli F, Scholtzova H, Spinner DS, Kascsak RB, et al. Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiol Dis 2009; 34:267 - 278
   PubMed Web of Science ®Google Scholar
• Feraudet-Tarisse C, Andreoletti O, Morel N, Simon S, Lacroux C, Mathey J, et al. Immunotherapeutic effect of anti-PrP monoclonal antibodies in transmissible spongiform encephalopathy mouse models: pharmacokinetic and pharmacodynamic analysis. J Gen Virol 91:1635 - 1645
   PubMed Web of Science ®Google Scholar
• Song CH, Furuoka H, Kim CL, Ogino M, Suzuki A, Hasebe R, et al. Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice. J Gen Virol 2008; 89:1533 - 1544
   PubMed Web of Science ®Google Scholar
• Zuber C, Mitteregger G, Pace C, Zerr I, Kretzschmar HA, Weiss S. Anti-LRP/LR antibody W3 hampers peripheral PrPSc propagation in scrapie infected mice. Prion 2007; 1:207 - 212
   PubMed Web of Science ®Google Scholar
• Luginbuhl B, Kanyo Z, Jones RM, Fletterick RJ, Prusiner SB, Cohen FE, et al. Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation. J Mol Biol 2006; 363:75 - 97
   PubMed Web of Science ®Google Scholar
• Padiolleau-Lefevre S, Alexandrenne C, Dkhissi F, Clement G, Essono S, Blache C, et al. Expression and detection strategies for an scFv fragment retaining the same high affinity than Fab and whole antibody: Implications for therapeutic use in prion diseases. Mol Immunol 2007; 44:1888 - 1896
   PubMed Web of Science ®Google Scholar
• Wuertzer CA, Sullivan MA, Qiu X, Federoff HJ. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther 2008; 16:481 - 486
   PubMed Web of Science ®Google Scholar
• Zuber C, Mitteregger G, Schuhmann N, Rey C, Knackmuss S, Rupprecht W, et al. Delivery of singlechain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J Gen Virol 2008; 89:2055 - 2061
   PubMed Web of Science ®Google Scholar
• Zuber C, Knackmuss S, Rey C, Reusch U, Rottgen P, Frohlich T, et al. Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases. Mol Immunol 2008; 45:144 - 1451
   PubMed Web of Science ®Google Scholar
• Rosset MB, Ballerini C, Gregoire S, Metharom P, Carnaud C, Aucouturier P. Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. J Immunol 2004; 172:5168 - 5174
   PubMed Web of Science ®Google Scholar
• Fernandez-Borges N, Brun A, Whitton JL, Parra B, Diaz-San Segundo F, Salguero FJ, et al. DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge. J Virol 2006; 80:9970 - 9976
   PubMed Web of Science ®Google Scholar
• Goni F, Prelli F, Schreiber F, Scholtzova H, Chung E, Kascsak R, et al. High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice. Neuroscience 2008; 153:679 - 686
   PubMed Web of Science ®Google Scholar
• Nikles D, Bach P, Boller K, Merten CA, Montrasio F, Heppner FL, et al. Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. J Virol 2005; 79:4033 - 4042
   PubMed Web of Science ®Google Scholar
• Steinman RM, Nussenzweig MC. Dendritic cells: features and functions. Immunol Rev 1980; 53:127 - 147
   PubMed Web of Science ®Google Scholar
• Steinman RM, Witmer MD. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci USA 1978; 75:5132 - 5136
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245 - 252
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17:138 - 146
   PubMedGoogle Scholar
• Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol 1994; 12:991 - 1045
   PubMed Web of Science ®Google Scholar
• Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220:129 - 150
   PubMed Web of Science ®Google Scholar
• Pulendran B, Palucka K, Banchereau J. Sensing pathogens and tuning immune responses. Science 2001; 293:253 - 256
   PubMed Web of Science ®Google Scholar
• Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Annu Rev Immunol 2000; 18:767 - 811
   PubMed Web of Science ®Google Scholar
• Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009; 27:3331 - 4
   PubMed Web of Science ®Google Scholar
• Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360:258 - 261
   PubMed Web of Science ®Google Scholar
• Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180:83 - 93
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colonystimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179:1109 - 1118
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319:1676 - 1680
   PubMed Web of Science ®Google Scholar
• Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328 - 332
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Angevin E, Tursz T. Dendritic cell-based immunotherapy of cancer. Ann Oncol 2000; 11:199 - 205
   PubMed Web of Science ®Google Scholar
• Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001; 98:8809 - 8814
   PubMed Web of Science ®Google Scholar
• Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007; 67:1842 - 1852
   PubMed Web of Science ®Google Scholar
• Fujisawa Y, Nabekura T, Nakao T, Nakamura Y, Takahashi T, Kawachi Y, et al. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells. Exp Dermatol 2009; 18:396 - 403
   PubMed Web of Science ®Google Scholar
• Wang RF. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol Rev 2002; 188:65 - 80
   PubMed Web of Science ®Google Scholar
• Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 207:651 - 667
   PubMed Web of Science ®Google Scholar
• Gregoire S, Logre C, Metharom P, Loing E, Chomilier J, Rosset MB, et al. Identification of two immunogenic domains of the prion protein—PrP— which activate class II-restricted T cells and elicit antibody responses against the native molecule. J Leukoc Biol 2004; 76:125 - 134
   PubMed Web of Science ®Google Scholar
• Bachy V, Ballerini C, Gourdain P, Prignon A, Iken S, Antoine N, et al. Mouse vaccination with dendritic cells loaded with prion protein peptides overcomes tolerance and delays scrapie. J Gen Virol 91:809 - 820
   PubMed Web of Science ®Google Scholar
• Rosset MB, Sacquin A, Lecollinet S, Chaigneau T, Adam M, Crespeau F, et al. Dendritic cell-mediatedimmunization with xenogenic PrP and adenoviral vectors breaks tolerance and prolongs mice survival against experimental scrapie. PLoS One 2009; 4:4917
   Web of Science ®Google Scholar
• Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7:145 - 173
   PubMed Web of Science ®Google Scholar
• Stockinger B, Veldhoen M, Martin B. Th17 T cells: linking innate and adaptive immunity. Semin Immunol 2007; 19:353 - 361
   PubMed Web of Science ®Google Scholar
• Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11:7 - 13
   PubMed Web of Science ®Google Scholar
• Bluestone JA, Mackay CR, O’Shea JJ, Stockinger B. The functional plasticity of T cell subsets. Nat Rev Immunol 2009; 9:811 - 816
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61:46 - 54
   PubMed Web of Science ®Google Scholar
• Gourdain P, Gregoire S, Iken S, Bachy V, Dorban G, Chaigneau T, et al. Adoptive transfer of T lymphocytes sensitized against the prion protein attenuates prion invasion in scrapie-infected mice. J Immunol 2009; 183:6619 - 6628
   PubMed Web of Science ®Google Scholar
• Kammertoens T, Blankenstein T. Making and circumventing tolerance to cancer. Eur J Immunol 2009; 39:2345 - 2353
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Restifo NP. Adoptive T cell therapy of cancer. Curr Opin Immunol 2009; 21:187 - 189
   PubMed Web of Science ®Google Scholar
• Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114:535 - 546
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21:215 - 223
   PubMed Web of Science ®Google Scholar
• Manz MG, Di Santo JP. Renaissance for mouse models of human hematopoiesis and immunobiology. Nat Immunol 2009; 10:1039 - 1042
   PubMedGoogle Scholar